Based on the evidence of current randomized phase III trials and our expert opinion in applying that evidence to practice, we have summarized the standard of care and preferred treatments for HR+/HER2– advanced breast cancer for patients relapsing more than and less than 12 months after completion of adjuvant ET, for patients with visceral metastases, and for frail patients. The gene discussed is ERBB2; the disease is breast cancer.